TOKYO & BOSTON — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. [Read more…]
Exclusive Investment Opportunity in Mexico with PRMedica Global
PRMedica Global, a distinguished British-incorporated company based in Los Cabos, Mexico, invites you to explore a premium investment opportunity in the growing field of regenerative medicine. With a specialized focus on advanced treatments using stem cells, exosomes, peptides, natural killer (NK) cells, and CAR-T cell therapies, PRMedica is at the forefront of medical innovation. Its treatments are designed to target a wide spectrum of health concerns, including orthopedic and musculoskeletal disorders, arthritis, autoimmune diseases, anti-aging solutions, neurological conditions, and more. [Read more…]
Cynata Introduces Critical Innovation into MSC Manufacturing
In the context of cell therapy, product innovation is the introduction of a cellular product that is new or has significantly improved characteristics or intended uses. Over the past decade, a great deal of attention has been given to cell therapy product innovation, as demonstrated by the thousands of cell therapy products that have now entered clinical trials worldwide.
In contrast, process innovation refers to the implementation of a new or significantly improved production or delivery method. In the context of cell therapy, process innovation has received much less attention from the marketplace. [Read more…]
Mesenchymal Stem Cells (MSCs): Definitions, Nomenclature, and Terms
To analyze the emerging global market for mesenchymal stem cells (MSCs), it is important to define the cell type. Broadly defined, MSCs are multi-potent stem cells that can differentiate into a diverse range of cell types. More specifically, MSCs are non-hematopoietic stromal cells that are capable of differentiating into, and assisting in the repair of, tissues of both intra-mesenchymal and extra-mesenchymal lineages.
Interestingly, MSCs exert their therapeutic effects primarily through paracrine signaling, a process where they secrete bioactive molecules such as cytokines, growth factors, and extracellular vesicles to influence nearby cells and tissues, rather than through direct differentiation into the specific target cells they aim to support or repair.
In contrast, other stem cell types, like iPSCs, tend to have greater utility because of their differentiation potential.
Stem Cell Treatments For COPD? Learn the Latest Breakthroughs
A diagnosis of chronic obstructive pulmonary disease (COPD) can be alarming, but thanks to stem cell treatments for COPD, the situation may not be dire. Once a patient develops COPD, it means that he or she has developed complications to existing breathing problems. The chronic disease happens when inflammation in the lung interferes with airflow.
Not being able to breathe properly and having frequent chest tightness can be distressing, especially when it is caused by a chronic disease, rather than a temporary illness like bronchitis. Thankfully, new options for treatment emerge every day. Among these options are stem cell treatments for COPD. [Read more…]
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 201
- Next Page »